This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / BioAge Labs Class Action Lawsuit
Business class action

BioAge Labs Class Action Lawsuit

Analysis based on 12 articles · First reported Feb 11, 2025 · Last updated Feb 27, 2025

Sentiment
-50
Attention
3
Articles
12
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted by the class action lawsuit against BioAge Labs, as it highlights potential risks in pharmaceutical IPOs and drug development. Investors in BioAge Labs are directly affected by the alleged damages from misleading statements, leading to a decline in investor confidence for the company.

Biotechnology Pharmaceuticals Legal Services
Event Summary

Rosen Law Firm has initiated a class action lawsuit against BioAge Labs, reminding investors of the lead plaintiff deadline of March 10, 2025. The lawsuit alleges that BioAge Labs made false and materially misleading statements in its initial public offering (IPO) registration statement on September 26, 2024. Specifically, BioAge Labs allegedly touted its lead product candidate azelaprag and its STRIDES clinical trial without disclosing the potential for liver transaminitis, which was observed in previous trials. Contrary to these representations, BioAge Labs discontinued the STRIDES Phase 2 study and halted further enrollment after subjects showed elevated liver enzyme levels, indicating potential organ damage. The lawsuit claims that investors suffered damages when these true details became public.

Key Actions
100 Rosen Law Firm filed lawsuit BioAge Labs
90 BioAge Labs discontinued trial
70 Rosen Law Firm reminds purchasers
Entities Involved
priv
BioAge Labs
BioAge Labs is the primary defendant in the class action lawsuit due to alleged misleading statements in its IPO registration regarding the safety and prospects of its drug candidate azelaprag, which led to the discontinuation of its STRIDES clinical trial.
Importance 100.0 Sentiment -70.0
stock
Eli Lilly and Company
Eli Lilly and Company's Chorus clinical development organization was mentioned as advising and assisting on the STRIDES trial, but its direct involvement in the alleged misrepresentations or the lawsuit is not detailed.
Importance 10.0 Sentiment 0.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
Relationships
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.